Imipenem

"Imipenem" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.

Descriptor ID	D015378
MeSH Number(s)	D02.065.589.099.124.300.500 D03.633.100.300.124.300.500
Concept/Terms	Imipenem Imipenem N-Formimidoylthienamycin N Formimidoylthienamycin Imipemide Imipenem, Anhydrous Imipenem, Anhydrous Anhydrous Imipenem Imipenem Anhydrous Anhydrous, Imipenem MK-0787 MK-0787 MK 0787 MK0787

Below are MeSH descriptors whose meaning is more general than "Imipenem".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Amides [D02.065]
Lactams [D02.065.589]
beta-Lactams [D02.065.589.099]
Carbapenems [D02.065.589.099.124]
Thienamycins [D02.065.589.099.124.300]
Imipenem [D02.065.589.099.124.300.500]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 2-Ring [D03.633.100]
beta-Lactams [D03.633.100.300]
Carbapenems [D03.633.100.300.124]
Thienamycins [D03.633.100.300.124.300]
Imipenem [D03.633.100.300.124.300.500]

Below are MeSH descriptors whose meaning is related to "Imipenem".

Below are MeSH descriptors whose meaning is more specific than "Imipenem".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Imipenem" by people in this website by year, and whether "Imipenem" was a major or minor topic of these publications.

Bar chart showing 23 publications over 9 distinct years, with a maximum of 5 publications in 2017 and 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2006	1	0	1
2010	1	0	1
2017	3	2	5
2018	4	0	4
2019	4	1	5
2020	1	0	1
2021	1	2	3
2022	0	1	1
2023	0	2	2

Below are the most recent publications written about "Imipenem" by people in Profiles.

Karlowsky JA, Lob SH, Siddiqui F, Akrich B, DeRyke CA, Young K, Motyl MR, Hawser SP, Sahm DF. In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018-2020. J Med Microbiol. 2023 Feb; 72(2).

View in: PubMed
Lob SH, Hawser SP, Siddiqui F, Alekseeva I, DeRyke CA, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland-SMART 2017-2020. Eur J Clin Microbiol Infect Dis. 2023 Mar; 42(3):365-370.

View in: PubMed
Karlowsky JA, Lob SH, DeRyke CA, Hilbert DW, Wong MT, Young K, Siddiqui F, Motyl MR, Sahm DF. In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020. Antimicrob Agents Chemother. 2022 05 17; 66(5):e0018922.

View in: PubMed
Karlowsky JA, Lob SH, Raddatz J, DePestel DD, Young K, Motyl MR, Sahm DF. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017. Clin Infect Dis. 2021 06 15; 72(12):2112-2120.

View in: PubMed
Lob SH, Hackel MA, Young K, Motyl MR, Sahm DF. Activity of imipenem/relebactam and comparators against gram-negative pathogens from patients with bloodstream infections in the United States and Canada - SMART 2018-2019. Diagn Microbiol Infect Dis. 2021 Aug; 100(4):115421.

View in: PubMed
Karlowsky JA, Lob SH, Young K, Motyl MR, Sahm DF. In Vitro Activity of Imipenem/Relebactam Against Gram-Negative Bacilli from Pediatric Patients-Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance program 2015-2017. J Pediatric Infect Dis Soc. 2021 Apr 03; 10(3):274-281.

View in: PubMed
Lob SH, Karlowsky JA, Young K, Motyl MR, Hawser S, Kothari ND, Sahm DF. In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015-2017. J Med Microbiol. 2020 Feb; 69(2):207-217.

View in: PubMed
Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF. In-vitro activity of imipenem/relebactam and key ?-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017. Int J Antimicrob Agents. 2020 Jan; 55(1):105841.

View in: PubMed
Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF. In vitro activity of imipenem/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015-2017. J Glob Antimicrob Resist. 2020 06; 21:223-228.

View in: PubMed
Lob SH, Karlowsky JA, Young K, Motyl MR, Hawser S, Kothari ND, Gueny ME, Sahm DF. Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17. J Antimicrob Chemother. 2019 08 01; 74(8):2284-2288.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement